Neoadjuvant chemohormonal therapy and radical prostatectomy in a patient with lymphogenic metastatic prostate cancer

Prostate cancer (PC) is now one of the most common malignancies among men. Radical prostatectomy is the most commonly used therapy option for patients with localized PC. The appropriateness of surgical treatment for locally advanced and lymphogenic metastatic PC remains controversial, as the probability of non-radical intervention increases significantly and the risk for disease progression becomes higher. At the same time, interest in surgical treatment in patients with PC at high risk of progression, including those with lymphogenic metastases has recently increased greatly. There are more and more studies demonstrating improved survival rates in patients with high-risk PC, including those with distant metastases, who have undergone radical prostatectomy and lymphadenectomy compared with a cohort of patients who have received only drug therapy In addition to the studies evaluating the efficiency of neoadjuvant therapy before surgery in patients with localized or locally advanced high-risk PC, there are also investigations considering this option in PC patients with lymphogenic metastases. The paper gives the results of a clinical observation that shows the high efficiency of a multimodal approach with neoadjuvant chemohormonal therapy, followed by surgical treatment in a patient with lymphogenic metastatic PC.

neoadjuvant chemohormonal therapy, surgical treatment for metastatic prostate cancer, combined chemohormonal therapy, docetaxel, novotax

1. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Malignant tumors in Russia in 2015 (morbidity and fatality). Eds.: А. D. Kaprin, V. V. Starinskiy, G. V. Petrova. Moscow: MNIOI im. P. A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 p. (In Russ.)].

2. Матвеев В. Б. Клиническая онкоурология. М., 2003. С. 525–570. [Matveev V. B. Clinical oncourology. Moscow, 2003. Pp. 525–570. (In Russ.)].

3. Thompson I. M., Tangen C., Basler J., Crawford E. D. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol 2002;168(3):1008–12. DOI: 10.1097/01.ju.0000026656.62692.67. PMID: 12187210.

4. Culp S. H., Schellhammer P. F., Williams M. B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65(6):1058–66. DOI: 10.1016/j.eururo.013.11.012. PMID: 24290503.

5. Febbo P. G., Richie J. P., George D. J. et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11:5233–40. DOI: 10.1158/1078–0432.CCR-05–0299. PMID: 16033841.

6. Chi K. N., Chin J. L., Winquist E. et al. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180(2):565–70. DOI: 10.1016/j. juro.2008.04.012. PMID: 18554663.

7. Носов А. К., Петров С. Б., Рева С. А. и др. Исследование безопасности и эффективности химиотерапии доцетакселом перед радикальной простатэктомией у больных раком предстательной железы промежуточного и высокого риска (наблюдение в течение 11,4 года). Онкоурология 2014;10(4): 52–61. [Nosov A. K., Petrov S. B., Reva S. A. et al. Results of a unicenter randomized study of the safety and efficiency of docetaxel chemotherapy before radical prostatectomy in patients with intermediate- and high-risk prostate cancer: An 11.4-year follow-up. Onkourologiya = Oncourology 2014;10(4):52–61. (In Russ.)].

8. Fizazi K., Lesaunier F., Delva R. et al. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG-12 trial. Eur J Cancer 2012;48(2):209–17. DOI: 10.1016/j.ejca.2011.10.015. PMID: 22119204.

9. Zurita A. J., Pisters L. L., Wang X. et al. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis 2015;18(3):276–80. DOI: 10.1038/pcan.2015.23. PMID: 26171883.

10. Eastham J. A., Kelly W. K., Grossfeld G. D., Small E. J. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62:55–62. DOI: 10.1016/j.urology.2003.09.052.